Company · Burlington, Ontario, Canada
Formative Pharma Inc.
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 16
- 16 authorized now
- Natural health products
- 0
- 0 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 20
Drug products
Authorized products first.
| Name | DIN | Status | Status since |
|---|---|---|---|
| BIVALIRUDIN FOR INJECTION | 02539586 | Marketed | |
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 02536714 | Marketed | |
| CABAZITAXEL FOR INJECTION | 02553783 | Marketed | |
| CABAZITAXEL FOR INJECTION | 02553791 | Marketed | |
| FULVESTRANT INJECTION | 02536293 | Marketed | |
| GANCICLOVIR FOR INJECTION | 02537168 | Marketed | |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 02534827 | Marketed | |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 02547856 | Marketed | |
| BUPIVACAINE HYDROCHLORIDE INJECTION USP | 02568500 | Approved | |
| BUPIVACAINE HYDROCHLORIDE INJECTION USP | 02568519 | Approved | |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 02570459 | Approved | |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 02570467 | Approved | |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 02570475 | Approved | |
| SUGAMMADEX INJECTION | 02545209 | Approved | |
| VORICONAZOLE FOR INJECTION | 02544350 | Approved | |
| XFUSOR | 02556472 | Approved |
Notices of Compliance
Newest first.
- VORICONAZOLE FOR INJECTIONAugust 27, 2026 · NOC 38266 · Supplement to an Abbreviated New Drug Submission (SANDS)
- CYCLOPHOSPHAMIDE FOR INJECTION USPJuly 31, 2026 · NOC 38035 · Abbreviated New Drug Submission (ANDS)
- BUPIVACAINE HYDROCHLORIDE INJECTION USPMay 25, 2026 · NOC 37605 · Abbreviated New Drug Submission (ANDS)
- BIVALIRUDIN FOR INJECTIONFebruary 10, 2026 · NOC 36872 · Supplement to an Abbreviated New Drug Submission (SANDS)
- SUGAMMADEX INJECTIONFebruary 9, 2026 · NOC 36859 · Supplement to an Abbreviated New Drug Submission (SANDS)
- FULVESTRANT INJECTIONJanuary 28, 2026 · NOC 36798 · Supplement to an Abbreviated New Drug Submission (SANDS)
- VORICONAZOLE FOR INJECTIONDecember 23, 2025 · NOC 36634 · Supplement to an Abbreviated New Drug Submission (SANDS)
- BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USPDecember 2, 2025 · NOC 36473 · Supplement to an Abbreviated New Drug Submission (SANDS)
- FULVESTRANT INJECTIONNovember 27, 2025 · NOC 36434 · Supplement to an Abbreviated New Drug Submission (SANDS)
- CABAZITAXEL FOR INJECTIONJune 18, 2025 · NOC 35545 · Supplement to an Abbreviated New Drug Submission (SANDS)
- BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USPApril 15, 2025 · NOC 35191 · Supplement to an Abbreviated New Drug Submission (SANDS)
- XFUSORMarch 20, 2025 · NOC 35051 · New Drug Submission (NDS)
- CABAZITAXEL FOR INJECTIONDecember 17, 2024 · NOC 34565 · Abbreviated New Drug Submission (ANDS)
- SUGAMMADEX INJECTIONAugust 6, 2024 · NOC 33757 · Abbreviated New Drug Submission (ANDS)
- BIVALIRUDIN FOR INJECTIONApril 23, 2024 · NOC 33104 · Supplement to an Abbreviated New Drug Submission (SANDS)
- VORICONAZOLE FOR INJECTIONJanuary 8, 2024 · NOC 32481 · Abbreviated New Drug Submission (ANDS)
- FULVESTRANT INJECTIONOctober 20, 2023 · NOC 31906 · Abbreviated New Drug Submission (ANDS)
- BIVALIRUDIN FOR INJECTIONJuly 14, 2023 · NOC 31220 · Abbreviated New Drug Submission (ANDS)
- GANCICLOVIR FOR INJECTIONApril 12, 2023 · NOC 30500 · Abbreviated New Drug Submission (ANDS)
- BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USPMarch 29, 2023 · NOC 30413 · Abbreviated New Drug Submission (ANDS)